Nasdaq gnlx.

So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily been active in studies pertaining to ovarian cancer. However, Genelux has also been forthcoming about its V2ACT Immunotherapy, which incorporates …52 Week Range 5.35 - 40.98. Market Cap $622.89M. Shares Outstanding 26.18M. Public Float 18.26M. Beta 1.10. Rev. per Employee $749.20K. P/E Ratio N/A. EPS -$0.58. Yield N/A.Jun 22, 2023 · WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ... The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 35.02 / share. This is an increase of 8.99% from the prior estimate of 32.13 dated August 31, 2023.Fintel. Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of ...

Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ...Web

WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. As of November 1, 2023, the average one-year price target for ...

Genelux Co. (NASDAQ:GNLX – Free Report) – Brookline Capital Management reduced their FY2023 earnings per share (EPS) estimates for shares of Genelux in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($1.03) per share for the year, down from their […]52 Week Range 5.35 - 40.98. Market Cap $622.89M. Shares Outstanding 26.18M. Public Float 18.26M. Beta 1.10. Rev. per Employee $749.20K. P/E Ratio N/A. EPS -$0.58. Yield N/A.Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Find the latest Insider Activity data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000® Index and small-cap Russell 2000® at the conclusion of the 2023 Russell indexes annual reconstitution, …

Stock analysis for Genelux Corp (GNLX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

10. 7. 2023 ... Therefore, a recommended dose was not established. WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) ...GNLX) stock’s latest price update. Genelux Corp (NASDAQ: GNLX)’s stock price has gone rise by 8.96 in comparison to its previous close of 14.51, however, the company has experienced a -15.41% decrease in its stock price over the last five trading days.Genelux Corp (NASDAQ:GNLX). 11.68. Delayed Data. As of Nov 29. +1.24 / +11.85%. Today's Change. 5.35. Today|||52-Week Range. 40.98. --. Year-to-Date. QuoteFind the latest news headlines from Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials... We explain how to buy Genelux Corporation Common Stock stock, compare the best stock trading platforms and use a detailed analysis to learn about (GNLX).

Shares of Genelux Corporation (NASDAQ:GNLX) got a boost, shooting 24% to $36.67. Sea Limited (NYSE:SE) shares were also up, gaining 16% to $76.09 after the company reported better-than-expected Q4 ...May 15, 2023 · WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ... WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in ...WebAug 28, 2023 · WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ... Jun 22, 2023 · WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...

Genelux Corporation ( Nasdaq: GNLX ), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering ...

WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the ...Genelux Co. ( NASDAQ:GNLX – Free Report) – Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for shares of Genelux in a report released on Monday, November 27th ...WebNov 20, 2023 · The public float for GNLX is 19.35M, and currently, shorts hold a 4.47% of that float. The average trading volume for GNLX on November 20, 2023 was 226.90K shares. GNLX) stock’s latest price update. The stock price of Genelux Corp (NASDAQ: GNLX) has dropped by -9.53 compared to previous close of 13.12. Genelux Corporation Common Stock (GNLX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. Nov 27, 2023 · Fintel. Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of ... NASDAQ:GNLX. Exchange/Ticker 2: N/A. Latest Market Cap: $311,897,408. BioCentury | Aug 28, 2023. Management Tracks. Kurt Graves takes top spot at i2o. Plus ...Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Nov 14, 2023 · WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ... GNLX | Complete Genelux Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Genelux Corp (NASDAQ:GNLX). 11.68. Delayed Data. As of Nov 29. +1.24 / +11.85%. Today's Change. 5.35. Today|||52-Week Range. 40.98. --. Year-to-Date. Quote

What happenedShares of Genelux (NASDAQ: GNLX) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech ...

WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...

Clinical-stage immuno-oncology company, Genelux (NASDAQ:GNLX) said that Lourie S. Zak will join the company as CFO, effective August 28, 2023.Ms. Zak will join Genelux with an extensive background ...Nov 29, 2023 · GNLX is trading at a 48% discount. Price $11.68. Nov 29, 2023. Fair Value $23.17. Nov 29, 2023 ... Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of November 1 ...WebWESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid …20. 11. 2023 ...Genelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the …View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news. WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...

WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President ...WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...The public float for GNLX is 19.35M, and currently, shorts hold a 4.47% of that float. The average trading volume for GNLX on November 20, 2023 was 226.90K shares. GNLX) stock’s latest price update. The stock price of Genelux Corp (NASDAQ: GNLX) has dropped by -9.53 compared to previous close of 13.12.Instagram:https://instagram. stocks below 2 dollarsbest malpractice insurance for nursespgboxwestern union in cuba The latest price target for Genelux ( NASDAQ: GNLX) was reported by Maxim Group on Tuesday, September 12, 2023. The analyst firm set a price target for 40.00 expecting GNLX to rise to within 12 ... start engine investmenticct stock forecast In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.WebNov 27, 2023 · The latest price target for Genelux ( NASDAQ: GNLX) was reported by Maxim Group on Tuesday, September 12, 2023. The analyst firm set a price target for 40.00 expecting GNLX to rise to within 12 ... key bank stocks 26. 10. 2023 ... Genelux raised $15.9 million in January pricing shares at $6 each. The stock (NASDAQ:GNLX) closed at $18.69 on Oct. 25, a 211.5% increase. Also ...Genelux Corp. GNLX, +12.02% has set terms for its initial public offering, in which the California-based biotechnology company focused on treating difficult-to-treat tumors could be valued at up ...Nov 20, 2023 · The public float for GNLX is 19.35M, and currently, shorts hold a 4.47% of that float. The average trading volume for GNLX on November 20, 2023 was 226.90K shares. GNLX) stock’s latest price update. The stock price of Genelux Corp (NASDAQ: GNLX) has dropped by -9.53 compared to previous close of 13.12.